Mesothelin Biomarker Risk Stratification for Severe COVID-19
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for predicting severe COVID-19 and long-haul COVID, and there is a need for targeted therapeutic approaches to manage the disease severity and complications.
Innovation Solution
The use of mesothelin (MSLN) as a biomarker in plasma samples to determine the risk of developing severe COVID-19 and long-haul COVID, with therapeutic interventions such as antibodies or CAR-T therapy targeting MSLN to mitigate disease severity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current biomarker methods are used for predicting severe COVID-19, then the diagnostic process is simple, but the prediction accuracy and reliability are insufficient
Solution Approach 1:
The patent segments the diagnostic process into multiple independent measurement components: detecting mesothelin levels, detecting ACE2 levels, and detecting the mesothelin/ACE2 ratio. This segmentation allows each component to be measured with high precision using established immunoassay techniques, while the combination of these segmented measurements provides comprehensive prediction accuracy for severe COVID-19 outcomes.
Solution Approach 2:
The patent introduces a new parameter (mesothelin/ACE2 ratio) in addition to individual protein levels. This parameter change transforms the diagnostic approach from measuring single biomarkers to measuring a composite ratio that captures the functional relationship between viral entry capability (ACE2) and pathological response (mesothelin), thereby improving prediction accuracy without requiring complex new measurement devices.
2Reliability
If targeted therapeutic approaches are developed, then treatment effectiveness is improved, but the complexity of therapeutic intervention increases
Solution Approach 1:
The patent enables preliminary identification of high-risk patients through biomarker detection before severe disease develops. This preliminary action allows clinicians to initiate targeted therapies (such as anticoagulation, anti-inflammatory agents, or immunomodulators) in advance, improving treatment effectiveness by intervening at an earlier stage when the disease is more responsive to therapy, rather than waiting for severe manifestations.
Solution Approach 2:
The mesothelin/ACE2 ratio serves as an intermediary marker that bridges viral infection detection and clinical outcome prediction. This intermediary allows targeted therapeutic strategies to be directed at specific pathophysiological pathways (e.g., endothelial protection, inflammation control) based on the ratio level, rather than applying blanket treatments, thereby improving effectiveness while maintaining manageable therapeutic complexity.
3Loss of time
If early intervention is implemented, then disease severity is reduced, but the timing precision for intervention is currently insufficient
Solution Approach 1:
The patent establishes a feedback mechanism where mesothelin and ACE2 levels are measured to calculate the mesothelin/ACE2 ratio, which then feeds back into risk stratification categories. This feedback loop enables dynamic monitoring of patient status and及时调整 of intervention timing. Patients with elevated ratios receive early intervention, while those with normal ratios can be monitored without aggressive treatment, optimizing the timing precision for intervention based on individual biomarker profiles.
Data Source
AI summary
Methods of using mesothelin levels is provided.